TICKERNERD
Menu
NMTCNMTCHealthcare · Medical Devices

NMTC Stock Forecast: NeuroOne Medical Technologies Corp. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$2.09
−2.79% on the day

The 3 Wall Street analysts covering NeuroOne Medical Technologies Corp. hold a median 12-month price target of $8 — +282.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 49 of 100 as at 22 Aug 2026 — in the lower half.

Market cap
$18.5M
Ticker Nerd rank
49 / 100
Median analyst target
$8.00
Analysts covering
3
Total return, dividends reinvested
1W
+7.7%
1M
+2.0%
YTD
−54.0%
1Y
−54.7%
From 52W high
−67.1%
From 52W low
+37.5%
$1.52
$6.36
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NMTC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores NeuroOne Medical Technologies Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
49 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
89
Revisions
70
Quality
59
Issuance
56
Volatility
52
Accruals
48
Value
36
Growth
24
Momentum
19

Size (89): Smaller than most of the companies we track.

Momentum (19): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NMTC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NMTC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00Oct 25Jan 26Apr 26Jul 26NMTCHigh $8.80Median $8.00Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $5.00Median $8.00High $8.80

The green dot is the last close — the median target sits +282.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Aug 2026Maxim GroupMaintainsBuy$13 → $5.00
13 May 2026Ladenburg ThalmannMaintainsBuy$1.60 → $8.00
13 May 2026Ladenburg ThalmannMaintainsBuy—
2 Mar 2026Jones TradingInitiatesBuy—
9 Sept 2025Maxim GroupInitiatesBuy—
5 May 2025Ladenburg ThalmannInitiatesBuy—
15 Aug 2023Alliance Global PartnersMaintainsBuy—
28 Mar 2022Craig-HallumDowngradeHold—
3 Dec 2021Alliance Global PartnersInitiatesBuy—
15 Nov 2021Craig-HallumInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NMTC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

NMTC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

NeuroOne Medical Technologies Corp. (NMTC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.8×

Cheaper than 88% of US stocks

Price / sales
1.5×

Cheaper than 61% of US stocks

Price / book
4.7×

Cheaper than 23% of US stocks

EV / EBITDA
−2.2×

Cheaper than 72% of US stocks

Growth & margins
Revenue growth (YoY)
16.3%

Higher than 65% of US stocks

Earnings growth (YoY)
34.3%

Higher than 69% of US stocks

Gross margin
53.2%

Higher than 66% of US stocks

Operating margin
−122.9%

Higher than 12% of US stocks

Net margin
−59.7%

Higher than 9% of US stocks

Returns & dividend
Return on equity
−124.7%

Higher than 11% of US stocks

Return on assets
−58.1%

Higher than 6% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

NMTC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
NMTCNeuroOne Medical Technologies Corp.$18.5M
49
PLSMPulsenmore Ltd.$20.0M
30
LFWDLifeward Ltd.$20.6M
21
CTSOCytoSorbents Corp.$23.2M
47
ADGMAdagio Medical Holdings, Inc.$13.7M
36
IRIXIRIDEX Corp.$13.0M
79
TELATELA Bio, Inc.$28.8M
27

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own NeuroOne Medical Technologies Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NMTC news & analysis

NeuroOne Medical Technologies Corporation (NMTC) Q3 2026 Earnings Call Transcript

Seeking Alpha · 13 Aug 2026neutral

NeuroOne Medical Technologies Corporation held its Q3 2026 earnings call, the transcript of which was published on Seeking Alpha. The call covered the company's quarterly financial results and business update for the period.

Why it matters — NMTC watchers would care because the earnings call transcript provides direct insight into the company's quarterly performance and management commentary.

FAQ

Frequently asked questions about NMTC stock

What is the NMTC stock price forecast for 2026-2027?

The 3 Wall Street analysts covering NeuroOne Medical Technologies Corp. have a median 12-month price target of $8, with estimates ranging from $5 to $8.8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NMTC stock a buy right now?

Of the 3 analysts covering NeuroOne Medical Technologies Corp., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks NeuroOne Medical Technologies Corp. 49 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NMTC?

As at 22 Aug 2026, NeuroOne Medical Technologies Corp. ranks 49 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (89 of 100).

Will NMTC stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +282.8% from the last close, and Ticker Nerd's factor model ranks NeuroOne Medical Technologies Corp. 49 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NMTC stock forecast for 2030?

No analyst covering NeuroOne Medical Technologies Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NMTC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $8.8 over the next 12 months.

How has NMTC stock performed over the past year?

NeuroOne Medical Technologies Corp. returned -54.7% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does NeuroOne Medical Technologies Corp. do?

NeuroOne Medical Technologies Corporation is a medical technology company that develops and markets cutting-edge neural surgical solutions. The company's primary focus lies in designing advanced electrode technology for recording and stimulating brain activity, which plays a crucial role in diagnosing and treating various neurological disorders.

What is the latest news on NMTC?

The most recent item we track (Seeking Alpha, 13 Aug 2026): "NeuroOne Medical Technologies Corporation (NMTC) Q3 2026 Earnings Call Transcript". NeuroOne Medical Technologies Corporation held its Q3 2026 earnings call, the transcript of which was published on Seeking Alpha. The call covered the company's quarterly financial results and business update for the period.

Company

About NeuroOne Medical Technologies Corp.

NeuroOne Medical Technologies Corporation is a medical technology company that develops and markets cutting-edge neural surgical solutions. The company's primary focus lies in designing advanced electrode technology for recording and stimulating brain activity, which plays a crucial role in diagnosing and treating various neurological disorders. These electrodes are used for electroencephalography (EEG), electrocorticography (ECoG), and brain stimulation therapies, impacting sectors such as neurology, neurosurgery, and neurodiagnostics. NeuroOne's innovative products aim to address unmet needs in the medical field by providing less invasive and more cost-effective solutions for brain surgeries and therapeutic treatments. Headquartered in the United States, NeuroOne Medical Technologies Corporation is at the forefront of enhancing the capabilities of neural procedures and treatments, potentially transforming how healthcare providers approach neurological conditions.

CEO Mr. David A. Rosa M.D. · 18 employees · United States · https://nmtc1.com